Potent and selective inhibitor of noradrenalin uptake (Ki values are 1.1, 129 and > 10000 nM for rat NET, SERT and DAT respectively). Displays > 1000-fold selectivity over α-adrenoceptors, 5-HT, dopamine and muscarinic ACh receptors. Orally active antidepressant.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 409.5. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.44 mL||12.21 mL||24.42 mL|
|5 mM||0.49 mL||2.44 mL||4.88 mL|
|10 mM||0.24 mL||1.22 mL||2.44 mL|
|50 mM||0.05 mL||0.24 mL||0.49 mL|
References are publications that support the products' biological activity.
Sacchetti et al (1999) Studies on the acute and chronic effects of reboxetine on extracellular noradrenaline and other monoamines in the rat brain. Br.J.Pharmacol. 128 1332 PMID: 10578149
Wong et al (2000) Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol.Psychiatry. 47 818 PMID: 10812041
Millan et al (2001) S33005, a novel ligand at both serotonin and norepinephrine transporters: I Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J.Pharmacol.Exp.Ther. 298 565 PMID: 11454918
Owen and Whitton (2003) Reboxetine modulates norepinephrine efflux in the frontal cortex of the freely moving rat: the involvement of α2 and 5-HT1A receptors. Neurosci.Lett. 348 171 PMID: 12932821
If you know of a relevant reference for Reboxetine mesylate, please let us know.
View Related Products by Product Action
Keywords: Reboxetine mesylate, supplier, Potent, selective, noradrenalin, noradrenaline, reuptake, inhibitors, inhibits, orally, active, Transporters, NET, Adrenergic, adrenaline, adrenalin, Monoamine, Neurotransmitter, Adrenergic, Transporters, Adrenergic, Transporters, Tocris Bioscience
4 Citations for Reboxetine mesylate
Citations are publications that use Tocris products. Selected citations for Reboxetine mesylate include:
Munari et al (2015) Brain Histamine Is Crucial for Selective Serotonin Reuptake Inhibitors' Behavioral and Neurochemical Effects. Neurochem Int 18 pyv045 PMID: 25899065
Hughes et al (2013) Endogenous analgesic action of the pontospinal noradrenergic system spatially restricts and temporally delays the progression of neuropathic pain following tibial nerve injury. Int J Neuropsychopharmacol 154 1680 PMID: 23707289
Hutchinson et al (2012) Differential regulation of MeCP2 phosphorylation in the CNS by dopamine and serotonin. Pain 37 321 PMID: 21956448
Ferreira et al (2012) Presynaptic CB(1) cannabinoid receptors control frontocortical serotonin and glutamate release--species differences. Theriogenology 61 219 PMID: 22609378
Do you know of a great paper that uses Reboxetine mesylate from Tocris? If so please let us know.
Reviews for Reboxetine mesylate
Average Rating: 5 (Based on 1 Review)
Have you used Reboxetine mesylate?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Reboxetine mesylate was dissolved in saline serum and 20 mg/kg (100 μL) were administered intraperitoneally to mice. After 24h, brain samples were taken and MCP-1 synthesis was analyzed by immunohistochemistry. This way, we confirmed that reboxetine treatment induces MCP-1 synthesis in cortical astrocytes.
In the figure, MCP-1 is labeled in red and GFAP in green.